Oǧuz F.Atmaca H.2024-07-222024-07-22202222285881http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12987Vaccination is one of the important approaches in the prevention and control of diseases. Although the capacity to present antigens other than the disease-specific antigen in the traditional vaccine composition provides a potential benefit by increasing its protective efficacy, many components that are not needed for the related disease are also transferred. These components can reduce vaccine activity by lowering immunity against protective antigens. The reasons such as the low effectiveness of traditional vaccines and the high cost of production and time-consuming reasons show that it is necessary to develop a new vaccine method for our world, which is struggling with epidemics almost every year. Among nucleic acids, mRNA has many advantages, such as genomic integration, induction of anti-DNA autoantibodies, and immune tolerance induced by long-term antigen expression. mRNA vaccines have become a therapeutic target for reasons such as efficacy, safety, fast and non-expensive production. The fact that mRNA triggers both humoral and cellular immunity and goes only to the cytoplasm, not to the nucleus, makes it highly efficient. The mRNA must cross the lipid bilayer barrier and entry to the cytoplasm where it is translated into protein. There are two main ways of mRNA vaccine delivery for this: ex vivo loading of mRNA into dendritic cells (DCs) and direct injection of mRNA with or without a carrier. Studies continue to understand which delivery system is therapeutically more efficient. Preclinical and clinical trials showed that mRNA vaccines trigger a long-lasting and safe immune response. © 2022 The Author (s).EnglishAll Open Access; Gold Open Access; Green Open Accesscell penetrating peptidecv 9103DNA antibodyglycoprotein gp 140influenza vaccinemessenger RNAnucleic acidnucleic acid vaccinepolyadenylic acidprotamineRNA polymeraseRNA vaccineunclassified drugZika virus vaccineantigen presenting cellantigen specificitycancer therapyclinical featureclinical trial (topic)comparative studydendritic celldrug delivery systemE.G7-OVA cell linehumanhumoral immunityimmune responseimmunological tolerancemessenger RNA synthesisnonhumanphase 1 clinical trial (topic)phase 2 clinical trial (topic)ReviewRNA purificationRNA sequenceRNA structurevaccinationvaccine developmentReview10.34172/apb.2022.028